Theseus Pharmaceuticals, Inc. (THRX): Price and Financial Metrics


Theseus Pharmaceuticals, Inc. (THRX): $6.99

-0.18 (-2.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add THRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

THRX Stock Price Chart Interactive Chart >

Price chart for THRX

THRX Price/Volume Stats

Current price $6.99 52-week high $24.54
Prev. close $7.17 52-week low $6.73
Day low $6.94 Volume 70,400
Day high $7.20 Avg. volume 69,101
50-day MA $10.33 Dividend yield N/A
200-day MA $0.00 Market Cap 270.53M

Theseus Pharmaceuticals, Inc. (THRX) Company Bio


Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


THRX Latest News Stream


Event/Time News Detail
Loading, please wait...

THRX Latest Social Stream


Loading social stream, please wait...

View Full THRX Social Stream

Latest THRX News From Around the Web

Below are the latest news stories about Theseus Pharmaceuticals Inc that investors may wish to consider to help them evaluate THRX as an investment opportunity.

Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14-18, 2022.

Yahoo | February 9, 2022

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company's lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestina

Yahoo | February 2, 2022

Theseus Pharma gains after insider purchase (NASDAQ:THRX)

Recently IPOed biopharmaceutical company Theseus Pharmaceuticals <> has added more than a tenth in value on below-average volume after the investment manager OrbiMed

Seeking Alpha | January 14, 2022

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | January 7, 2022

Theseus Pharmaceuticals up 24% following two insider buys

No summary available.

Seeking Alpha | December 23, 2021

Read More 'THRX' Stories Here

THRX Price Returns

1-mo -14.44%
3-mo -30.79%
6-mo -51.15%
1-year N/A
3-year N/A
5-year N/A
YTD -44.87%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5629 seconds.